高维医药

High-Dimensional Medicine (HDM) is a biotechnology company headquartered in Hangzhou, China, that leverages artificial intelligence and high-dimensional biological data to advance drug discovery. The company's proprietary platform focuses on high-dimensional phenotypic screening (HDPS), which enables the systematic identification of novel therapeutic candidates for complex and "undruggable" targets. HDM primarily develops first-in-class small molecule drugs, with a strategic focus on oncology and metabolic diseases. By integrating high-throughput experimental biology with advanced computational modeling, the company aims to streamline the transition from target identification to clinical development. HDM has successfully secured significant venture capital funding from prominent investors to support its innovative R&D pipeline.